Status:
UNKNOWN
Quantitative mpMRI to Predict Metastatic Potential of Prostate Cancer
Lead Sponsor:
Radboud University Medical Center
Conditions:
Prostate Cancer
Eligibility:
MALE
50+ years
Brief Summary
The primary aim of this study is to assess the potential of quantitative MRI measurements to predict localized prostate cancer T-stage and disease spread to nodes (N-stage) by correlating quantitative...
Detailed Description
Patients diagnosed with prostate cancer will likely not die from the primary tumor, but from (extended) metastatic disease. One of the first steps towards extended metastatic disease is the presence o...
Eligibility Criteria
Inclusion
- Histologically proven primary cancer of the prostate, based on prostate biopsy-core analysis.
- Patient is scheduled and fit for PSMA-PET/CT
- Age≥50 years. Ability to give voluntary written informed consent to participate in this study.
Exclusion
- Contraindication for MRI-scanning, i.e. claustrophobia, intracranial metal clips, metallic bodies in the eye, implanted electric and electronic devices not eligible for MRI (pacemakers, insulin pumps, cochlear implants, neurostimulators).
- Prior prostate cancer treatment.
- Prior pelvic surgery, associated with pelvic lymphadenopathy
- Presence of any medical condition that in the opinion of the investigator/treating physician will affect patients' clinical status by participating in this trial.
- Inability to lie still for 45 minutes or comply with imaging.
- The patient is already enrolled in one or more concurrent studies, which could confound the results of this study, according to the investigators.
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05252806
Start Date
July 1 2022
End Date
March 1 2023
Last Update
June 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud university medical centre
Nijmegen, Netherlands